California Public Employees Retirement System Cuts Stock Position in Boston Scientific Corporation $BSX

Key Points

• California Public Employees Retirement System trimmed its Boston Scientific stake by 4.4% in Q3, selling 151,051 shares and leaving it with 3,260,023 shares worth about $318.3 million.
• CEO Michael F. Mahoney sold 160,901 shares on Feb 2 at an average of $93.49 (≈$15.04 million), reducing his ownership by 10.23%.
• Boston Scientific reported an EPS beat ($0.80 vs. $0.78) and 15.9% YoY revenue growth to $5.29 billion, with Q1 2026 and FY2026 guidance provided, but faces analyst price‑target cuts and active class‑action litigation alleging misstatements about electrophysiology volumes.

California Public Employees Retirement System cut its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 4.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,260,023 shares of the medical equipment provider's stock after selling 151,051 shares during the quarter. California Public Employees Retirement System owned about 0.22% of Boston Scientific worth $318,276,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of BSX. FWL Investment Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth approximately $26,000. Steph & Co. acquired a new stake in Boston Scientific in the third quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp raised its stake in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 170 shares during the period. Financial Consulate Inc. acquired a new position in shares of Boston Scientific during the third quarter worth $25,000. Finally, United Community Bank lifted its position in shares of Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 147 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $69.15 on Friday. The company has a market cap of $102.61 billion, a P/E ratio of 35.64, a PEG ratio of 0.97 and a beta of 0.69. The business has a 50 day moving average of $82.47 and a two-hundred day moving average of $93.29. Boston Scientific Corporation has a 52 week low of $67.56 and a 52 week high of $109.50. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analysts' expectations of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business's quarterly revenue was up 15.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company's stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.50% of the stock is owned by corporate insiders.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Weiss Ratings cut shares of Boston Scientific from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Wednesday, February 4th. Mizuho cut their price target on Boston Scientific from $140.00 to $115.00 and set an "outperform" rating on the stock in a research note on Thursday, February 5th. TD Cowen reduced their price target on Boston Scientific from $115.00 to $100.00 and set a "buy" rating for the company in a report on Monday, February 2nd. The Goldman Sachs Group set a $99.00 price objective on Boston Scientific in a research note on Thursday, February 5th. Finally, Robert W. Baird cut their target price on Boston Scientific from $118.00 to $101.00 and set an "outperform" rating on the stock in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Boston Scientific has an average rating of "Moderate Buy" and an average target price of $108.00.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.